Clinical Trial Update: NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus plus cisplatin in triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Everolimus (everolimus)

Snippet

Sponsor: Jenny C. Chang, MD | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-07-09